The effects of perfusion conditions on melphalan distribution in the isolated perfused rat hindlimb hearing a human melanoma xenograft

British Journal of Cancer

Volumn 75, Issue 8, 1997, Pages 1160-1166

  Wu, Z Y ^a   Smithers, B M ^a   Parsons, P G ^b   Roberts, M S ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

Isolated perfused tumour bearing rat hindlimb; Melphalan; Perfusion flow; Protein binding; Tissue distribution

Indexed keywords

BOVINE SERUM ALBUMIN; BUFFER; DEXTRAN 40; MELPHALAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG TUMOR LEVEL; DRUG UPTAKE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HINDLIMB; ISOTOPE LABELING; MALE; MELANOMA; NONHUMAN; PRIORITY JOURNAL; RAT; REGIONAL PERFUSION; SKIN; TISSUE BLOOD FLOW; TISSUE DISTRIBUTION; XENOGRAFT;

EID: 0030975331     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.200     Document Type: Article

References (33)

1. Benckhuijsen C, Varossieau FJ, Hart AAM, Wieberdink J and Noordhoek J (1985) Pharmacokinetics of melphalan in isolated perfusion of the limbs. J Pharm Exp Ther 237: 583-588
2. Benckhuijsen C, Kroon BBR, Van Geel AN and Weiberdink J (1988) Regional perfusion treatment with melphalan for melanoma in a limb: an evaluation of drug kinetics. Eur J Surg Oncol 14: 157-163
3. Chang SY, Alberts DS, Farquhar D, Melnick LR, Walson PD and Salmon SE (1978) Hydrolysis and protein binding of melphalan. J Pharm Sci 67: 682-684
4. Clark J, Grabs AJ, Parsons PG, Smithers BM, Addison RS and Roberts MS (1994) Melphalan uptake, hyperthermic synergism and drug resistance in a human cell culture model for the isolated limb perfusion of melanoma. Melanoma Res 4: 365-370
5. Cross SE, Wu ZY and Roberts MS (1994) Effect of perfusion flow rate on the tissue uptake of solutes after dermal application using the rat isolated perfused limb preparution. J Pharm Pharnmtol 46: 844-850
6. Egerton WS (1982) Regional cytotoxic arterial perfusion for recurrent malignant melanoma limbs. In Malignant Skin Tumours, Emmet AJ and O'Rourke MGE (eds), pp. 183-184. Churchill Livingstone: Edinburgh
7. Englund NE, Lindstedt E and Vang JO (1971) Regional perfusion in treatment of sarcomas of the extremities. Acta Chir Scand 137: 243-252
8. Fontijne WPJ, De Vroes J and Mook PH (1984) Improved tissue perfusion during pressure regulated hyperthermic regional isolated perfusion in dogs. J Surg Oncol 26: 69-79
9. Fontijne WPJ, Mook PH, Schraffordt Koops H, Oldhoff J and Wildevuur CHRH (1985) Improved tissue perfusion during pressure regulated hyperthermic regional isolated perfusion. Cancer 55: 1455-1461
10. Goss PD and Parsons PG (1977) The effect of hyperthermia and melphalan on survival ot human fibroblast strains and melanoma cell lines. Cancer Res 37: 152-155
11. Hales JRS (1974) Radioactive microsphere techniques for studies of the circulation. Clin Exp Pharmacol Physiol Suppl 1: 31-46
12. Hales JRS, King RB and Fawcett AA (1979) Observations on the validity of using 'NEN-TRAC' microspheres for measuring organ blood flow. Pflugers Arch 379: 295-296
13. Heymann MA, Payne BD, Huffman JI and Rudolph AM (1977) Blood flow measurements with radionuclide-labelled particles. Prog-Cardiovasc-Dis 20: 55-79
14. Kettelhack CH, Kraus TH. Manner M and Schlag P (1990) Hyperthermic limb perfusion for malignant melanoma and soft tissue sarcoma. Eur J Surg Oncol 16: 370-375
15. Klaase JM, Kroon BBR, Beijnen JH, Van Slooten GW and Van Dongen JA (1994a) Melphalan tissue concentrations in patients treated with regional isolated perfusion for melanoma of the lower limb. Br J Cancer 70: 151-153
16. Klaase JM, Kroon BBR, Van Geel AN, Eggermont AMM, Franklin HR and Hart GA (1994b) Patient and treatment related factors associated with acute regional toxicity after isolated perfusion for melanoma of the extremities. Am J Surg 167: 618-620
17. Krenientz ET, Carter RD, Sutherland CM and Muchmore JH (1987) Chemotherapy by regional perfusion for limb melanoma. Am J Surg 53: 133-140
18. Kroon BBR (1988) Regional isolation perfusion in melanoma of the limbs: accomplishments, unsolved problems, future. Eur J Surg Oncol 14: 101-110
19. Lejeune FJ, Lienard D and Ewalenko P (1988) Hyperthermic isolation perfusion of the limb with eytostatics after surgical excision of sarcomas, World J Surg 12: 345-348
20. Morgan DJ and Xu CL (1994) Effect of perlusate pH on reduction of quinidine capillary permeability by albumin in isolated perfused rat heart. Pharm Res 11: 1820-1824
21. Omlor G, Schellhase KP, Molter MD, Motsch H and Walter P (1990) Hemodynamics as indicators of flow rates during isolated limb perfusion. Reg Cancer Treat 3: 103-106
22. Parsons PG, Carter FB, Morrison L and Mary SR (1982) Mechanism of melphalan resistance developed in vitro in human melanoma cells. Cancer Rex 41: 1525-1530
23. Scott RN, Robinson B, Clutterbuck RD, Bishop JA, Newell DR, Selby PJ and Westbury G (1987) A comparison of melphalan levels achieved in isolated limb perfusion and systemic high dose therapy. J Exp Clin Cancer Res 6: 161-165
24. Scott RN, Blackie R, Kerr DJ, Wheldon TE, Kaye EB, Mackie RM and McKay AJ (1990) Melphalan in isolated limb perfusion for malignant melanoma, bolus or divided dose, tissue levels, the pH effect. In Progress in Regional Cancer Therapy, Jakesz R and Rainer H (eds), pp. 195-200. Springer: Berlin
25. Scott RN, Blackie R, Kerr DJ, Hughes J, Burnside G, Mackie RM, Byrne DS and MeKay AJ (1992a) Melphalan concentration and distribution in the tissues of tumour-bearing limbs treated by isolated limb perfusion. Eur J Cancer 28A: 1811-1813
26. Scott RN, Kerr DJ, Blackie R, Hughes J, Burnside G, Mackie RM, Byrne DS and McKay AJ (1992b) The pharmacokinetic advantages of isolated limb perfusion with melphalan for malignant melanoma. Br J Cancer 66: 159-166
27. Thompson JF, Good PD and Kam PCA (1994a) Hyperthermic isolated perfusion in the treatment of melanoma: technical aspects. Reg Cancer Treat 7: 147-154
28. Thompson JE, Lai DTM, Ingvar C and Kam PCA (1994b) Maximizing efficacy and minimizing toxicity in isolated limb perfusion for melanoma. Melanoma Res 4: 45-50
29. Vrouenraets BC, Klaase JM, Kroon BB, van-Geel BN, Eggermont AM and Franklin HR (1995) Long-term morbidity after regional isolated perfusion with melphalan for melanoma of the limbs. The influence of acute regional toxic reactions. Arch Surg 130: 43-17
30. Wu ZY, Rivory LP and Roberts MS (1993) Physiological pharmacokinetics of solutes in the isolated perfused rat hindlimb: characterization of the physiology with changing perfusate flow, protein content, and temperature using statistical moment analysis. J Pharmacokin Biopharm 21: 653-688
31. Wu ZY, Thompson MJ, Addison RS, Grabs AJ, Smithers BM and Roberts MS (1995a) HPLC assay for the measurement of melphalan and its hydrolysis products in perfusate and plasma and melphalan in tissues from human and rat isolated limb perfusions. J Chronmatogr B 673: 267-279
32. Wu ZY, Cross SE and Roberts MS (1995b) Influence of physiochemical parameters and perfusate flow rate on the distribution of solutes in the isolated perfused rat hindlimb determined by the impulse-response technique. J Pharm Sci 84: 1020-1027
33. Wu ZY, Smithers BM, Parsons PG and Roberts MS (1996) Isolated limb perfusion with melphalan for human melanoma xenograft in the hindlimb of nude rats: a surviving animal model. Melanoma Res (in press)